You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What information does Lilly have for a patient who injects tirzepatide beyond the label?
There is no information on injecting tirzepatide IV or IM, or using injection sites other than the abdomen, thigh, or upper arm. There is no information on any differences of injecting between the abdomen, thigh, and/or upper arm.
See important safety information, including boxed warning, in the attached prescribing information.
Approved Injection Information
Labelling Information
Inject tirzepatide under the skin (subcutaneously) in the stomach (abdomen), thigh, or another person should inject in the back of the upper arm.1
Change (rotate) injection sites with each dose. You may use the same area of your body but be sure to choose a different injection site in that area.1
Safety and Efficacy Between Approved Injection Sites
Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm.1,2
Eli Lilly and Company cannot comment on safety and efficacy differences when using one approved injection site versus another because this has not been studied.
Patients should consult with their health care providers if they have questions about which of the approved injection site(s) is best. Health care providers may consider the patient's individual factors and medical history.
Unapproved Injection Types or Locations
Injecting in Other Areas of the Body
Lilly has no clinical information regarding injecting the medication in other locations because there are no studies injecting in areas other than the abdomen, thigh, or upper arm.
Other Injection Types
Do not inject tirzepatide intramuscularly (IM) or intravenously (IV). The effect of IM or IV injection of tirzepatide has not been evaluated by Lilly; therefore, no data is available regarding this topic.7
- Muscular tissues are typically more vascularized than SC tissues, which might accelerate drug absorption and influence dose response.3 It has been previously observed that IM injection of insulins led to higher fluctuations in glycemic level in patients with diabetes, and increased risk of hypoglycemia.4-6 The relevance of these results for tirzepatide is unknown.
- After an IV injection, all the medicine is delivered directly into the blood stream.
Adequate needle length should be selected according to the specific population to be administered to reduce the risk of IM or IV injection.7
Enclosed Prescribing Information
MOUNJARO® (tirzepatide) Injection, for subcutaneous use, Lilly
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
- MOUNJARO [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
- A study of tirzepatide at different injection sites in participants with different body sizes. ClinicalTrials.gov identifier: NCT04050670. Updated May 6, 2023. Accessed August 5, 2026. https://clinicaltrials.gov/study/NCT04050670
- Usach I, Martinez R, Festini T, Peris JE. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36(11):2986-2996. https://doi.org/10.1007/s12325-019-01101-6
- Hirsch L, Byron K, Gibney M. Intramuscular risk at insulin injection sites--measurement of the distance from skin to muscle and rationale for shorter-length needles for subcutaneous insulin therapy. Diabetes Technol Ther. 2014;16(12):867-873. https://doi.org/10.1089/dia.2014.0111
- Karges B, Boehm BO, Karges W. Early hypoglycaemia after accidental intramuscular injection of insulin glargine. Diabet Med. 2005;22(10):1444-1445. https://doi.org/10.1111/j.1464-5491.2005.01654.x
- Vaag A, Handberg A, Lauritzen M, Henriksen JE, Pedersen KD, Beck-Nielsen H. Variation in absorption of NPH insulin due to intramuscular injection. Diabetes Care. 1990;13(1):74-76. https://doi.org/10.2337/diacare.13.1.74
- Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: July 20, 2026